Drug intelligence / Profile preview

Suvaxyn PRRS MLV

Development stage: Unknown
Lead developer: Zoetis
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal

Overview

Suvaxyn PRRS MLV is a veterinary vaccine containing a modified live Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), genotype 1, strain 96V198. It is formulated as a lyophilisate and solvent for suspension for injection in pigs. The vaccine is designed for the active immunisation of clinically healthy pigs (including piglets from one day of age, gilts, and sows) to reduce viraemia and nasal shedding caused by infection with European strains of PRRS virus (genotype 1). The mechanism of action involves stimulating the pig’s immune system to develop protective immunity against PRRSV-1. Immunity develops within three weeks after vaccination and lasts up to 26 weeks in fattening pigs. The product is used intramuscularly or nasally, with mass vaccination possible in herds where European PRRS virus prevalence has been established[1][5][6][7].

Brand names: Suvaxyn PRRS MLV
Other names: Modified live PRRSV, strain 96V198

Beyond the preview

Go deeper on Suvaxyn PRRS MLV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suvaxyn PRRS MLV.

Explore the full profile